PAVmed CEO Lishan Aklog Reports 5.1% Stake Following Restricted Stock Grant

On April 9, 2026, Dr. Lishan Aklog, Chairman and CEO of PAVmed Inc. (PAVM), filed a Schedule 13D reporting a new 5.1% beneficial ownership stake in the company. This position consists of 369,068 shares of Common Stock. The acquisition was primarily driven by a grant of 350,000 shares of restricted Common Stock on April 2, 2026, issued under the company's Seventh Amended and Restated Long-Term Incentive Equity Plan in consideration for his executive services. Dr. Aklog's total holdings include 357,614 shares held directly, along with indirect ownership through HCFP/AG LLC (45 shares), Pavilion Venture Partners LLC (9,904 shares), and 10 shares held by his children. Additionally, the reported figure includes 1,495 shares issuable upon the exercise of stock options. The filing indicates that the shares were acquired for investment purposes. Dr. Aklog is also party to several option and restricted stock agreements with various vesting dates ranging from 2026 to 2032.